We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Medical Sciences/Expert perspectives and practices on the clinical use of cilnidipine + telmisartan in the management of hypertension with comorbid diabetes in Indian settings
PeriodicalsMedical Sciences

Expert perspectives and practices on the clinical use of cilnidipine + telmisartan in the management of hypertension with comorbid diabetes in Indian settings

Checking your access to this record.

Abstract & Overview

Objective: To evaluate the clinician’s preferences and practices regarding the use of cilnidipine and telmisartan combination therapy in the management of hypertension and comorbid diabetes in Indian settings. Methodology: The cross-sectional study consisted of a 24-item, multiple-response questionnaire-based survey, gathering expert opinion on current practices, clinical observations, and experiences related to the use of combination therapy of cilnidipine and telmisartan in routine Indian settings for managing hypertension. The survey respondents were specialists with expertise in managing hypertension. The data were analyzed using descriptive statistics. Results: The survey involved 533 clinicians of which the majority (63.2%) reported that the cilnidipine + telmisartan combination reduces blood pressure (BP), has a cardioprotective effect, attenuates high blood glucose levels, and offers vasoprotection. Most clinicians (91.2%) indicated that cilnidipine was the most commonly used calcium channel blocker (CCB) for patients with hypertension and diabetes, and 73% reported telmisartan as the preferred combination for diabetic hypertension. Additionally, 91% favored cilnidipine as the preferred CCB with angiotensin receptor blocker (ARB) for managing hypertensive patients with renal comorbidities. About 76% recommended cilnidipine + telmisartan for diabetic hypertensive patients. Reduction in pedal edema was noted as a benefit of this combination by 40% of clinicians. A significant majority (67.2%) of the experts considered the combination excellent for BP management and cardioprotection. As reported by 81% of the respondents, factors improving patient outcomes included smoking cessation, exercise, a healthy salt-restricted diet, and medication compliance. Conclusion: The survey corroborated the increased preference among clinicians for the combination of cilnidipine and telmisartan in managing hypertension in patients with both diabetes and renal conditions. The survey findings also highlighted its beneficial effects, including effective lowering of blood pressure, regulation of blood glucose levels, and cardioprotective and vasoprotective effects.

Cite this record

Manjula S, Krishna Kumar M (2024). Expert perspectives and practices on the clinical use of cilnidipine + telmisartan in the management of hypertension with comorbid diabetes in Indian settings. International Journal of Cardiology Sciences, 6(1), 74–80. https://doi.org/10.33545/26649020.2024.v6.i1a.53

Copy in another style

S, M., & M, K. K. (2024). Expert perspectives and practices on the clinical use of cilnidipine + telmisartan in the management of hypertension with comorbid diabetes in Indian settings. International Journal of Cardiology Sciences, 6(1), 74–80. https://doi.org/10.33545/26649020.2024.v6.i1a.53
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.